Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

36.95
Delayed Data
As of 4:00pm ET
 -0.24 / -0.65%
Today’s Change
33.60
Today|||52-Week Range
54.23
-3.15%
Year-to-Date
EpiPen Competitor, Auvi-Q, Will Hit the Market in February
12:32pm / TheStreet.com - Paid Partner Content
Mylan/Biocon's Herceptin Biosimilar under Review in the U.S.
Jan 12 / Zacks.com - Paid Partner Content
Integrated Investment Consultants, LLC Buys Vanguard FTSE Emerging Markets, Mylan NV,...
Jan 18 / GuruFocus News - Paid Partner Content
Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again
Jan 12 / Zacks.com - Paid Partner Content
Examining Volkswagen and Fiat Chrysler's Emissions Cheating Scandals
Jan 13 / Zacks.com - Paid Partner Content
Cigna is no longer covering pricey EpiPen
Jan 11 / CNNMoney.com
Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlig...
Jan 13 / Zacks.com - Paid Partner Content
Valeant Streamlines Portfolio with Skincare Brands Sale
Jan 11 / Zacks.com - Paid Partner Content
Will This Be a Genius or Foolish Move for Johnson & Johnson?
Jan 13 / MotleyFool.com - Paid Partner Content
Trump: Drug companies 'getting away with murder'
Jan 11 / CNNMoney.com
Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News
Jan 13 / Zacks.com - Paid Partner Content
Valeant to Sell Dendreon Unit to Sanpower for $820 Million
Jan 10 / Zacks.com - Paid Partner Content
Stock Market Roundup, Jan. 12: AMZN Jobs, FCAU Cheating, AKS & X Tank
Jan 12 / Zacks.com - Paid Partner Content
Momenta (MNTA) to Receive $50M Under CSL Collaboration
Jan 06 / Zacks.com - Paid Partner Content
CVS Debuts Cheap EpiPen Alternative
Jan 12 / Zacks.com - Paid Partner Content
These big companies had a terrible 2016
Dec 27 / CNNMoney.com
CVS cuts cost for generic EpiPen competitor
Jan 12 / CNNMoney.com